These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10613674)

  • 1. Acute myocardial infarction following administration of recombinant activated factor VII (Novo Seven) in a patient with haemophilia A and inhibitor.
    Peerlinck K; Vermylen J
    Thromb Haemost; 1999 Dec; 82(6):1775-6. PubMed ID: 10613674
    [No Abstract]   [Full Text] [Related]  

  • 2. Myocardial infarction occurring in a case of acquired haemophilia during the treatment course with recombinant activated factor VII.
    Guillet B; Pinganaud C; Proulle V; Dreyfus M; Lambert T
    Thromb Haemost; 2002 Oct; 88(4):698-9. PubMed ID: 12362252
    [No Abstract]   [Full Text] [Related]  

  • 3. Clinical efficacy of recombinant activated factor VII (rFVIIa) during acute bleeding episode and surgery in a patient with acquired hemophilia A with high inhibitor titer.
    Franchini M; Capra F; Capelli C; de Maria E; Lippi G; Gandini G
    Haematologica; 2001 Apr; 86(4):E12. PubMed ID: 11325664
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful management of massive intraperitoneal bleeding in a hemophilia A patient with inhibitor by surgical debridement of the incomplete hematoma and administration of recombinant factor VIII and activated factor VII.
    Koyama T; Nagao T; Tsunozaki H; Arai M; Miura O
    Pathophysiol Haemost Thromb; 2006; 35(5):405-7. PubMed ID: 17230044
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous infusion of recombinant factor VIIa in hemophilic patients with inhibitors: safety, monitoring, and cost effectiveness.
    Schulman S;
    Semin Thromb Hemost; 2000; 26(4):421-4. PubMed ID: 11092218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distal deep venous thrombosis in a hemophilia A patient with inhibitor and severe infectious disease, 18 days after recombinant activated factor VII transfusion.
    Van der Planken MG; Schroyens W; Vertessen F; Michiels JJ; Berneman ZN
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):367-70. PubMed ID: 12032404
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo haemostatic effects of activated prothrombin complex concentrate and recombinant factor VIIa in a haemophilia A patient with inhibitors.
    Grossmann R; Geisen U; Walter U
    Haemophilia; 2001 Nov; 7(6):589-91. PubMed ID: 11851758
    [No Abstract]   [Full Text] [Related]  

  • 8. The concept of recombinant factor VIIa megadose for treating bleeding episodes in high-titer inhibitor patients with hemophilia: toward an expanding indication?
    Negrier C
    J Thromb Haemost; 2003 Mar; 1(3):423-4. PubMed ID: 12871444
    [No Abstract]   [Full Text] [Related]  

  • 9. Prophylactic treatment with FEIBA of a haemophilia A patient with inhibitor: what are the costs, what are the benefits?
    Siegmund B; Richter H; Pollmann H
    Haemophilia; 2005 Nov; 11(6):638-41. PubMed ID: 16236116
    [No Abstract]   [Full Text] [Related]  

  • 10. NovoSeven for non-hemophilia hemostasis.
    Med Lett Drugs Ther; 2004 Apr; 46(1181):33-4. PubMed ID: 15114252
    [No Abstract]   [Full Text] [Related]  

  • 11. Myocardial injury in patients with intracerebral hemorrhage treated with recombinant factor VIIa.
    Sugg RM; Gonzales NR; Matherne DE; Ribo M; Shaltoni HM; Baraniuk S; Noser EA; Grotta JC
    Neurology; 2006 Sep; 67(6):1053-5. PubMed ID: 17000976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective treatment with recombinant factor VIIa of severe bleeding due to acquired factor VIII inhibitor and acquired thrombocytopathy.
    Conesa V; Mompel A; Lopez F; Marín F; Ruiz J; Navarro F; Gomez A
    Am J Hematol; 2002 Aug; 70(4):329-30. PubMed ID: 12210816
    [No Abstract]   [Full Text] [Related]  

  • 13. rFVIIa (Novoseven): the new panacea?
    Ickx BE
    Acta Anaesthesiol Belg; 2003; 54(4):333-5. PubMed ID: 14719355
    [No Abstract]   [Full Text] [Related]  

  • 14. MedWatch: an important instrument for postlicensing surveillance.
    Aledort LM
    J Thromb Haemost; 2006 Jul; 4(7):1637. PubMed ID: 16839372
    [No Abstract]   [Full Text] [Related]  

  • 15. Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease.
    Basso IN; Keeling D
    Blood Coagul Fibrinolysis; 2004 Sep; 15(6):503-4. PubMed ID: 15311160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
    Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
    Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant FVIIa.
    Hedner U
    Vox Sang; 2004 Jul; 87 Suppl 2():25-8. PubMed ID: 15209873
    [No Abstract]   [Full Text] [Related]  

  • 18. Accidental overdosage of recombinant factor VIIa due to mistaken package size.
    Heuer L; Blumenberg D
    Thromb Haemost; 2004 Jun; 91(6):1249-50. PubMed ID: 15175815
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity--a rebuttal.
    Makris M; Van Veen JJ
    J Thromb Haemost; 2005 Apr; 3(4):818-9; author reply 819. PubMed ID: 15842387
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of bleeding in acquired haemophilia A with recombinant activated factor VII: does one size fit all? A report of four cases.
    Di Capua M; Coppola A; Nardo A; Cimino E; Di Minno MN; Tufano A; Mormile R; Burzo ML; Di Minno G; Cerbone AM
    Blood Transfus; 2015 Apr; 13(2):328-32. PubMed ID: 24960652
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.